WASHINGTON - A panel of advisers to the U.S. Centers for Disease Control and Prevention will continue its two-day meeting on Thursday to discuss specific recommendations about who should get Pfizer’s COVID-19 booster shot — and when — following a sign-off by the U.S.
Food and Drug Administration for certain Americans. The FDA on Wednesday evening authorized the booster doses for those 65 and older, younger adults with underlying health conditions and those in jobs that put them at high risk for COVID-19.
But more regulatory hurdles lie ahead before the dispensing of boosters can begin — including the CDC panel’s recommendations and an eventual sign-off by that agency as well.